This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bioterrorism  • Alert me on articles by topic  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2001;285:284.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Although a number of other viral infections claim many more lives each year, Ebola virus is particularly feared because it spreads easily and kills swiftly and ruthlessly, before the body has time to muster an effective immune response. Now, a report that a new vaccine developed by researchers from the National Institutes of Health (NIH) appeared to protect monkeys from infection with the deadly virus is an encouraging sign of the feasibility of developing a protective human vaccine (Nature. 2000;408:605-609).

The vaccination strategy involves a one-two punch, aimed at eliciting both antibodies and T cells directed against Ebola virus proteins. The first involves an injection of a multistrain DNA vaccine (targeting the three known fatal Ebola virus strains, Zaire, Sudan, and Ivory Coast) to "prime" the immune system. This is followed by a second vaccine, a weakened adenovirus vector engineered to express surface protein from the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?